Daratumumab is a recombinant IgG1k monoclonal antibody that binds to CD38 and leads to cell apoptosis. Daratumumab was granted orphan drug designation for the treatment of multiple myeloma, diffuse large B cell lymphoma, follicular lymphoma, and mantle cell lymphoma.